AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2865417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminohydroxypropylidene diphosphonate (APD)
Number of subjects: 39
Study 31029558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma IL-8 levels (Trajectory group 1)
Number of subjects: 58
Study 31029558 — intervention group
Group type: COMPARATOR
Intervention: Trajectory group 2 (higher IL-8 levels)
Number of subjects: 58
Study 31029558 — intervention group
Group type: COMPARATOR
Intervention: Trajectory group 3 (highest IL-8 levels)
Number of subjects: 58
Study 29127137 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption (ATI)
Number of subjects: 0
Study 26847108 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) and methotrexate (MTX)
Number of subjects: 120
Study 26847108 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) with additional synthetic disease modifying anti‐rheumatic drugs (sDMARDs)
Number of subjects: 120
Study 25677175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention (TSI)
Number of subjects: 45
Study 25677175 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine Artery Doppler Screening (UADS)
Number of subjects: 45
Study 25677175 — intervention group
Group type: COMPARATOR
Intervention: Face to face midwifery visits
Number of subjects: 45
Study 23447917 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Pycnogenol twice daily for 3 months
Number of subjects: 170
Study 23447917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 21904014 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived cells (5 cc)
Number of subjects: 48
Study 21904014 — intervention group
Group type: COMPARATOR
Intervention: Whole blood (5 cc)
Number of subjects: 48
Study 18498663 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole or 20 mg rabeprazole for 8 days (treatment group)
Number of subjects: 106
Study 18498663 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group measured as integrated acidity)
Number of subjects: 106
Study 17052624 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plain
Number of subjects: 102
Study 17052624 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80.000 epinephrine
Number of subjects: 102
Study 17052624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser irradiation
Number of subjects: 102
Study 17052624 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac
Number of subjects: 102
Study 17052624 — intervention group
Group type: COMPARATOR
Intervention: Regular postoperative recommendations
Number of subjects: 102
Study 12713711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetazolamide (125 mg BID)
Number of subjects: 197
Study 12713711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 11498723 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg NF
Number of subjects: 63
Study 11498723 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg NF
Number of subjects: 63
Study 11498723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9755351 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotapes (three experimental types)
Number of subjects: 258
Study 9755351 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 258
Study 8141572 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1-g intravenous intermittent infusions every 8 h
Number of subjects: 12
Study 3411648 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 0
Study 3411648 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream
Number of subjects: 0
Study 29782648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatments for AK
Number of subjects: 109
Study 28501063 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 0
Study 28501063 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 0
Study 25315022 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with Unna's boot
Number of subjects: 17
Study 23370085 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (n=20)
Number of subjects: 40
Study 23370085 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n=20)
Number of subjects: 40
Study 21983154 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (Q/LAIV), n=1200
Number of subjects: 1800
Study 21983154 — intervention group
Group type: COMPARATOR
Intervention: Trivalent live attenuated influenza vaccine (T/LAIV), n=600
Number of subjects: 1800
Study 17928802 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron daily for 8 weeks
Number of subjects: 180
Study 17928802 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg iron daily for 8 weeks
Number of subjects: 180
Study 17928802 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg iron daily for 8 weeks
Number of subjects: 180
Study 17928802 — intervention group
Group type: COMPARATOR
Intervention: 20 mg iron group
Number of subjects: 180
Study 17928802 — intervention group
Group type: COMPARATOR
Intervention: 40 mg iron group
Number of subjects: 180
Study 17120694 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective pictures with unpleasant, neutral, and pleasant contents
Number of subjects: 61
Study 17120694 — intervention group
Group type: COMPARATOR
Intervention: Affective pictures of two sizes (120 x 90 cm and 52 x 42 cm)
Number of subjects: 61
Study 15646910 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg of oral midazolam (MDZ) 20 minutes prior to treatment
Number of subjects: 28
Study 15646910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg oral midazolam (MDZ) with 3.7 mg/kg of hydroxyzine (MDZH) 30 minutes before treatment
Number of subjects: 28
Study 15646910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyzine (3.7 mg/kg) with MDZ (0.3 mg/kg)
Number of subjects: 28
Study 11349929 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncycloplegic near retinoscopy
Number of subjects: 29
Study 11349929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegia with tropicamide 1%
Number of subjects: 29
Study 11349929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegia with cyclopentolate 1%
Number of subjects: 29
Study 9146780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg three times daily
Number of subjects: 96
Study 9146780 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 96
Study 7993154 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric fluconazole
Number of subjects: 0
Study 7993154 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial EGD and fluconazole
Number of subjects: 0
Study 7993154 — intervention group
Group type: COMPARATOR
Intervention: Initial EGD and fluconazole compared to empiric fluconazole
Number of subjects: 0
Study 31772401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group ('B') - Combined Spinal Epidural Anaesthesia (CSEA) after preprocedural lumbar ultrasound scan
Number of subjects: 210
Study 31772401 — intervention group
Group type: COMPARATOR
Intervention: Control group ('A') - CSEA given by blind conventional technique
Number of subjects: 210
Study 28796278 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching (hold-relax-with agonist contraction)
Number of subjects: 15
Study 28796278 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 15
Study 28796278 — intervention group
Group type: COMPARATOR
Intervention: No stretching
Number of subjects: 15
Study 27025297 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized household allergen reduction
Number of subjects: 247
Study 27025297 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 247
Study 24773573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback with motivational interviewing
Number of subjects: 68
Study 24773573 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback without motivational interviewing
Number of subjects: 68
Study 24773573 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 68
Study 22057205 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotaxic location puncture and dilation procedures
Number of subjects: 400
Study 22057205 — intervention group
Group type: COMPARATOR
Intervention: Traditional procedure
Number of subjects: 400
Study 20482275 — intervention group
Group type: EXPERIMENTAL
Intervention: High-maize 260 resistant starch (12 g added RS)
Number of subjects: 15
Study 20482275 — intervention group
Group type: COMPARATOR
Intervention: Control bread (no added RS)
Number of subjects: 15
Study 18391573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 193
Study 18391573 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy
Number of subjects: 193
Study 16368449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 2297
Study 16368449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 2297
Study 16368449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study 12357148 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin concentration‐based anticoagulation management (Hepcon HMS)
Number of subjects: 200
Study 12357148 — intervention group
Group type: COMPARATOR
Intervention: Activated clotting time‐based heparin management
Number of subjects: 200
Study 10348536 — intervention group
Group type: EXPERIMENTAL
Intervention: trapidil (400 mg/d) + ticlopidine (500 mg) for the first month
Number of subjects: 118
Study 10348536 — intervention group
Group type: COMPARATOR
Intervention: aspirin (325 mg/d) + ticlopidine (500 mg) for the first month
Number of subjects: 118
Study 7806173 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/Kg intravenously)
Number of subjects: 58
Study 7806173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 1719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular dextran 40
Number of subjects: 0
Study 1719734 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 40/0.5
Number of subjects: 0
Study 1719734 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl-infusions
Number of subjects: 0
Study 1719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheologically effective substances (low-molecular dextran 40 and 6% hydroxyethyl starch 40/0.5)
Number of subjects: 0
Study 1719734 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero or next to zero therapy
Number of subjects: 0
Study 6176354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with MFC plus OK‐432 (group A)
Number of subjects: 83
Study 6176354 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy with OK‐432 alone (group B)
Number of subjects: 83
Study 31310775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mcg/kg intravenous ghrelin
Number of subjects: 0
Study 31310775 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mcg/kg intravenous ghrelin
Number of subjects: 0
Study 31310775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29888729 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentations (Group V, n = 33)
Number of subjects: 99
Study 29888729 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory presentations (Group A, n = 33)
Number of subjects: 99
Study 29888729 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n = 33)
Number of subjects: 99
Study 26364889 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoscopy training using OtoSim simulator; 1-hour teaching session
Number of subjects: 57
Study 25049338 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session intervention based on trauma-focused cognitive behavior therapy
Number of subjects: 105
Study 25049338 — intervention group
Group type: COMPARATOR
Intervention: 1-session active comparison intervention (education about NICU and parenting)
Number of subjects: 105
Study 21942377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal condition (participants instructed to think about their physiological arousal as functional and adaptive)
Number of subjects: 0
Study 21942377 — intervention group
Group type: COMPARATOR
Intervention: Attention reorientation (control condition)
Number of subjects: 0
Study 21942377 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control condition)
Number of subjects: 0
Study 20124144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-only intervention
Number of subjects: 662
Study 20124144 — intervention group
Group type: COMPARATOR
Intervention: Control group (health-promotion intervention)
Number of subjects: 662
Study 20124144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 662
Study 20124144 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour comprehensive intervention
Number of subjects: 662
Study 20124144 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour comprehensive intervention
Number of subjects: 662
Study 18035192 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Number of subjects: 189
Study 18035192 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg QD for 4 weeks, then increased to 10 mg QD if necessary for 4 weeks
Number of subjects: 189
Study 18035192 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate
Number of subjects: 189
Study 18035192 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 189
Study 16055647 — intervention group
Group type: EXPERIMENTAL
Intervention: Short exposure to subliminally primed concepts
Number of subjects: 0
Study 16055647 — intervention group
Group type: COMPARATOR
Intervention: Long exposure to subliminally primed concepts
Number of subjects: 0
Study 16055647 — intervention group
Group type: EXPERIMENTAL
Intervention: Short exposure to descriptively inapplicable trait primes
Number of subjects: 0
Study 16055647 — intervention group
Group type: COMPARATOR
Intervention: Long exposure to descriptively inapplicable trait primes
Number of subjects: 0
Study 12189228 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (900 mg daily, orally for 18 days)
Number of subjects: 5
Study 12189228 — intervention group
Group type: COMPARATOR
Intervention: irinotecan alone (without SJW)
Number of subjects: 5
Study 10449886 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive systemic sclerosis (PSS) patients
Number of subjects: 20
Study 10449886 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study 8678247 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 8678247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 50
Study 8678247 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 2104083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.d.s.)
Number of subjects: 10
Study 2104083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg in the evening) without indomethacin
Number of subjects: 10
Study 2104083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg in the evening) with concurrent indomethacin
Number of subjects: 10
Study 2104083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 370586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (200 mg per kilogram of body weight per day)
Number of subjects: 64
Study 370586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 370586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 64
Study 31590988 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus platinum-etoposide
Number of subjects: 537
Study 31590988 — intervention group
Group type: COMPARATOR
Intervention: Platinum-etoposide
Number of subjects: 537
Study 29471877 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention based on individual risk for depression, including communication of risk factors and tailored psychosocial program by GPs.
Number of subjects: 3326
Study 29471877 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3326
Study 27817766 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (0.25 mg initial dose and 0.25 mg/h for maintenance)
Number of subjects: 126
Study 27817766 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 μg/(kg·h) continuous intravenous pumping)
Number of subjects: 126
Study 27817766 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative hemostasis (Control group)
Number of subjects: 126
Study 22879577 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning (EF) remediation training with game elements
Number of subjects: 40
Study 22879577 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study 22297610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of hip flexors/extensors
Number of subjects: 24
Study 22297610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue of ankle plantar/dorsiflexors
Number of subjects: 24
Study 22297610 — intervention group
Group type: COMPARATOR
Intervention: Visual condition (eyes closed)
Number of subjects: 24
Study 20738871 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 0
Study 20738871 — intervention group
Group type: COMPARATOR
Intervention: Conventional process
Number of subjects: 0
Study 17592905 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents (adjunctive treatment)
Number of subjects: 1500
Study 17592905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjunctive treatment)
Number of subjects: 1500
Study 15976798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV) within 6 hours
Number of subjects: 56
Study 15976798 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 56
Study 15976798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 56
Study 12818732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 25 mg once daily
Number of subjects: 2
Study 12818732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 100 mg once daily
Number of subjects: 2
Study 12818732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 11119398 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 8
Study 11119398 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.5 mg/kg)
Number of subjects: 8
Study 11119398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (20 microg/kg/min)
Number of subjects: 8
Study 11119398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (40 microg/kg/min)
Number of subjects: 8
Study 11119398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8867274 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (4 x 7 capsules/day)
Number of subjects: 80
Study 8867274 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (2 x 50 mg capsules/day)
Number of subjects: 80
Study 1729933 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 17201
Study 3931465 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide once daily
Number of subjects: 18
Study 3931465 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide twice daily
Number of subjects: 18
Study 3931465 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide once daily
Number of subjects: 18
Study 31278117 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein-based nutritional supplement enriched with leucine and vitamin D
Number of subjects: 150
Study 31278117 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital diet without nutritional support
Number of subjects: 150
Study 26674360 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 1063
Study 26674360 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 1063
Study 27769282 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure Management Application (BPMAP)
Number of subjects: 132
Study 27769282 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 132
Study 23907291 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant single agent doxorubicin
Number of subjects: 94
Study 23907291 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 + CLP
Number of subjects: 94
Study 23907291 — intervention group
Group type: COMPARATOR
Intervention: Pathology-based classification
Number of subjects: 94
Study 22554024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHPP)
Number of subjects: 0
Study 22554024 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-chlorproguanil-dapsone (ASCD)
Number of subjects: 0
Study 22554024 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 0
Study 19196813 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg x kg(‐1) human alpha(1)‐AT (Prolastin)
Number of subjects: 77
Study 19196813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 17893869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 1546
Study 17893869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Number of subjects: 1546
Study 17893869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention plus Phone (TIP)
Number of subjects: 1546
Study 17893869 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1546
Study 16293984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 66
Study 16293984 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 66